These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 9237704)

  • 1. Lamivudine-resistant human immunodeficiency virus type 1 variants (184V) require multiple amino acid changes to become co-resistant to zidovudine in vivo.
    Nijhuis M; Schuurman R; de Jong D; van Leeuwen R; Lange J; Danner S; Keulen W; de Groot T; Boucher CA
    J Infect Dis; 1997 Aug; 176(2):398-405. PubMed ID: 9237704
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel human immunodeficiency virus type 1 reverse transcriptase mutational pattern confers phenotypic lamivudine resistance in the absence of mutation 184V.
    Hertogs K; Bloor S; De Vroey V; van Den Eynde C; Dehertogh P; van Cauwenberge A; Stürmer M; Alcorn T; Wegner S; van Houtte M; Miller V; Larder BA
    Antimicrob Agents Chemother; 2000 Mar; 44(3):568-73. PubMed ID: 10681319
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence of primary resistance to zidovudine and lamivudine in drug-naive human immunodeficiency virus type-1 infected patients: high proportion of reverse transcriptase codon 215 mutant in circulating lymphocytes and free virus.
    Trabaud MA; Leriche-Guerin K; Regis C; Bordes I; Cotte L; Detmer J; Kolberg J; Ritter J; Trépo C
    J Med Virol; 2000 Jul; 61(3):352-9. PubMed ID: 10861645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The M184V mutation in HIV-1 reverse transcriptase (RT) conferring lamivudine resistance does not result in broad cross-resistance to nucleoside analogue RT inhibitors.
    Miller V; Stürmer M; Staszewski S; Gröschel B; Hertogs K; de Béthune MP; Pauwels R; Harrigan PR; Bloor S; Kemp SD; Larder BA
    AIDS; 1998 May; 12(7):705-12. PubMed ID: 9619801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of 3TC in HIV clinical trials may be due in part to the M184V substitution in 3TC-resistant HIV-1 reverse transcriptase.
    Wainberg MA; Hsu M; Gu Z; Borkow G; Parniak MA
    AIDS; 1996 Dec; 10 Suppl 5():S3-10. PubMed ID: 9030390
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resistance pathways of human immunodeficiency virus type 1 against the combination of zidovudine and lamivudine.
    Theys K; Deforche K; Libin P; Camacho RJ; Van Laethem K; Vandamme AM
    J Gen Virol; 2010 Aug; 91(Pt 8):1898-1908. PubMed ID: 20410311
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selection by AZT and rapid replacement in the absence of drugs of HIV type 1 resistant to multiple nucleoside analogs.
    Lukashov VV; Huismans R; Jebbink MF; Danner SA; de Boer RJ; Goudsmit J
    AIDS Res Hum Retroviruses; 2001 Jun; 17(9):807-18. PubMed ID: 11429122
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term foscarnet therapy remodels thymidine analogue mutations and alters resistance to zidovudine and lamivudine in HIV-1.
    Mathiesen S; Dam E; Roge B; Joergensen LB; Laursen AL; Gerstoft J; Clavel F
    Antivir Ther; 2007; 12(3):335-43. PubMed ID: 17591023
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual resistance to zidovudine and lamivudine in patients treated with zidovudine-lamivudine combination therapy: association with therapy failure.
    Miller V; Phillips A; Rottmann C; Staszewski S; Pauwels R; Hertogs K; de Béthune MP; Kemp SD; Bloor S; Harrigan PR; Larder BA
    J Infect Dis; 1998 Jun; 177(6):1521-32. PubMed ID: 9607829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of zidovudine resistance mutations on virologic response to treatment with zidovudine-lamivudine-ritonavir: genotypic analysis of human immunodeficiency virus type 1 isolates from AIDS clinical trials group protocol 315.ACTG Protocol 315 Team.
    Kuritzkes DR; Sevin A; Young B; Bakhtiari M; Wu H; St Clair M; Connick E; Landay A; Spritzler J; Kessler H; Lederman MM
    J Infect Dis; 2000 Feb; 181(2):491-7. PubMed ID: 10669331
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug resistance and drug combination features of the human immunodeficiency virus inhibitor, BCH-10652 [(+/-)-2'-deoxy-3'-oxa-4'-thiocytidine, dOTC].
    Taylor DL; Ahmed PS; Tyms AS; Wood LJ; Kelly LA; Chambers P; Clarke J; Bedard J; Bowlin TL; Rando RF
    Antivir Chem Chemother; 2000 Jul; 11(4):291-301. PubMed ID: 10950391
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy.
    Larder BA; Kemp SD; Harrigan PR
    Science; 1995 Aug; 269(5224):696-9. PubMed ID: 7542804
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiretroviral efficacy and virological profile of a zidovudine/lamivudine/tenofovir disoproxil fumarate combination therapy in antiretroviral-naive patients.
    Masquelier B; Neau D; Boucher S; Lavignolle-Aurillac V; Schrive MH; Recordon-Pinson P; Ragnaud JM; Fleury H
    Antivir Ther; 2006; 11(6):827-30. PubMed ID: 17310827
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emergence of dual resistance to zidovudine and lamivudine in HIV-1-infected patients treated with zidovudine plus lamivudine as initial therapy.
    Kuritzkes DR; Shugarts D; Bakhtiari M; Poticha D; Johnson J; Rubin M; Gingeras TR; Kennedy M; Eron JJ
    J Acquir Immune Defic Syndr; 2000 Jan; 23(1):26-34. PubMed ID: 10708053
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel polymorphism at codon 333 of human immunodeficiency virus type 1 reverse transcriptase can facilitate dual resistance to zidovudine and L-2',3'-dideoxy-3'-thiacytidine.
    Kemp SD; Shi C; Bloor S; Harrigan PR; Mellors JW; Larder BA
    J Virol; 1998 Jun; 72(6):5093-8. PubMed ID: 9573280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanistic studies examining the efficiency and fidelity of DNA synthesis by the 3TC-resistant mutant (184V) of HIV-1 reverse transcriptase.
    Feng JY; Anderson KS
    Biochemistry; 1999 Jul; 38(29):9440-8. PubMed ID: 10413520
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and significance of the HIV-1 reverse transcriptase M184V mutation during combination therapy with lamivudine, zidovudine, and protease inhibitors.
    Catucci M; Venturi G; Romano L; Riccio ML; De Milito A; Valensin PE; Zazzi M
    J Acquir Immune Defic Syndr; 1999 Jul; 21(3):203-8. PubMed ID: 10421243
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficient inhibition of both syncytium-inducing and non-syncytium-inducing wild-type HIV-1 by lamivudine in vivo.
    van 't Wout AB; Ran LJ; Nijhuis M; Tijnagel JM; de Groot T; van Leeuwen R; Boucher CA; Schuitemaker H; Schuurman R
    AIDS; 1998 Jul; 12(10):1169-76. PubMed ID: 9677166
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of genotypic resistance to nucleoside analogues in antiretroviral-naive and antiretroviral-experienced HIV-infected patients in Spain.
    Gómez-Cano M; Rubio A; Puig T; Pérez-Olmeda M; Ruiz L; Soriano V; Pineda JA; Zamora L; Xaus N; Clotet B; Leal M
    AIDS; 1998 Jun; 12(9):1015-20. PubMed ID: 9662197
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased drug susceptibility of HIV-1 reverse transcriptase mutants containing M184V and zidovudine-associated mutations: analysis of enzyme processivity, chain-terminator removal and viral replication.
    Naeger LK; Margot NA; Miller MD
    Antivir Ther; 2001 Jun; 6(2):115-26. PubMed ID: 11491416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.